Therefore, in the future, it would apply the iron-chelating agents and antioxidants or SystemXC-inhibitors and GPXS inhibitors to regulate ferroptosis of tumor cells for malignant mutations related to the NF2/YAP signaling pathway. Here, NF2 is linked to neoplasm.